Head & Neck Cancers

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.

A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.

Canadian researchers are investigating standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy with panitumumab in locally SCCHN.

The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.

Patients (and even clinicians) often don't know which facilities are considered leaders in the treatment of various types of cancer, and a bit of detective work is generally required.

The tyrosine kinase inhibitor cabozantinib met its primary endpoint of progression-free survival in patients with advanced medullary thyroid cancer.

Dr. Ezra Cohen, from the University of Chicago, Discusses Treating Medullary Thyroid Cancer

Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

The use of PET/CT scans in the detection of early recurrence in patients with squamous cell carcinoma of the head and neck remains an open question, despite recent research suggesting beneficial results.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

US investigators have found that suicide rates in recent years have significantly increased in patients with oral cavity and oropharyngeal cancer.

Erin McMenamin, MSN, from the Hospital of the University of Pennsylvania, on HPV-related Head & Neck Cancer Prognosis

Treatment of head and neck cancer often leaves patients with aftereffects that are bothersome at the very least and life-altering at their worst.

Minimally invasive transoral robotic surgery, used alone or combined with adjuvant therapy, provides good functional and oncologic outcomes in patients with oropharyngeal squamous cell carcinoma.